High-risk patients (score ≥ 2) experienced lower 3-year PFS/OS than low-risk patients, underscoring that complementary biology captured by tumor burden, mucin expression, cytokine signaling, and host inflammatory tone is clinically actionable for CRT risk stratification in locally advanced cervical cancer. The gene discussed is MUC5AC; the disease is cervical cancer.